Denali Therapeutics Shares Are Trading Lower After the Company Announced Topline Results for Regimen G of the Phase 2/3 HEALEY ALS Platform Trial Evaluating EIF2B Agonist DNL343 in the Treatment of Amyotrophic Lateral Sclerosis Did Not Meet Its...

Denali Therapeutics的股票在公司宣佈Phase 2/3 HEALEY ALS平台試驗的G方案的頂線結果後出現下跌，該試驗評估了EIF20億激動劑DNL343在治療肌萎縮側索硬化症中的效果，但未達到預期...

Benzinga · 01/07 08:23

Denali Therapeutics Shares Are Trading Lower After the Company Announced Topline Results for Regimen G of the Phase 2/3 HEALEY ALS Platform Trial Evaluating EIF2B Agonist DNL343 in the Treatment of Amyotrophic Lateral Sclerosis Did Not Meet Its Primary Endpoint.

Denali Therapeutics的股票在公司公佈用於評估治療肌萎縮性側索硬化症的第2/3階段HEALEY ALS平台試驗的G方案的主要結果後交易下跌，該試驗評估了EIF20億激動劑DNL343，但未達到其主要終點。

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。